

Patient: [REDACTED]  
 DOB: [REDACTED] Age: [REDACTED] Gender: [REDACTED]  
 Patient Identifiers: [REDACTED]  
 Visit Number (FIN): [REDACTED]


Client: [REDACTED]  
 Physician: [REDACTED]

ARUP Test Code: 2008320  
 Collection Date: 01/06/2017  
 Received in lab: 01/07/2017  
 Completion Date: 01/07/2017

### Patient History \*

<u>Collection Date</u>	<u>Infliximab Activity (IFX) ug/mL</u>	<u>Neutralizing Antibody (IFX NAb) Titer</u>	<u>Accession Number</u>
1/6/2017	26.30	Not Detected	17-006-401808
7/13/2016	13.57	Not Detected	16-195-402925
2/17/2016	1.39	Not Detected	16-048-402909
2/16/2016	1.60	Not Detected	16-047-401673
10/6/2015	20.32	Not Detected	15-279-402707
8/3/2015	1.47	Not Detected	15-215-400835

### Infliximab Activity versus Neutralizing Antibody Titer



Cutoff values are 0.65 ug/mL for infliximab and 1:20 for antidrug antibody (NAb).

\*Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information on this chart appears incomplete, please consult this patient's prior charts.



Patient: [REDACTED]  
 ARUP Accession: 17-006-401808

# Infliximab Activity and Neutralizing Antibody

Patient: [REDACTED] | Date of Birth: [REDACTED] | Gender: [REDACTED] | Physician: [REDACTED]  
Patient Identifiers: [REDACTED] | Visit Number (FIN): [REDACTED]

## Interpretive Comments

**Interpretive Data:** This test measures the capacity of infliximab to neutralize TNF-alpha activity. Additionally, infliximab neutralizing antibodies (NAb) are titered (reporting the highest dilution of patient sera in which NAb activity is detected).

This test is used to evaluate secondary response failures to infliximab therapy. Secondary response failure is defined as loss of clinical response after initial improvement of clinical signs and symptoms. Therapeutic decision should rest on both the clinical response and the knowledge of the fate of the drug including the emergence of immunogenicity in individual patients.

Circulating infliximab levels have been shown to vary considerably between patients. These differences relate to route and frequency of administration and patient-related features such as age, gender, weight, drug metabolism, and concomitant medications such as methotrexate and other immunosuppressants.

IF Infliximab Activity is...	AND Infliximab Neutralizing Antibody Titer is...	THEN...
Not Detected	Not Detected	A higher dosage of infliximab or shortening the dosing interval may be appropriate.
Not Detected	1:20 or greater	A change to another anti-TNF-alpha drug may be appropriate.
0.65 ug/mL or greater	Not Detected	A change to another type of therapy (not targeting TNF-alpha) may be appropriate.
0.65 ug/mL or greater	1:20 or greater	Repeat testing is suggested to rule out decreasing infliximab activity and/or increasing infliximab neutralizing antibodies.

METHODOLOGIES USED: Cell Culture, Cell function assay involving cell stimulation, Quantitative Chemiluminescent Immunoassay, Semi-Quantitative Chemiluminescent Immunoassay

See Compliance Statement B: [www.aruplab.com/CS](http://www.aruplab.com/CS)



Patient: [REDACTED]  
ARUP Accession: 17-006-401808